| |
|
|
|
|
|
Zymeworks Reports 2020 Year-End Financial Results
|
|
Vancouver, BC, March 1, 2021--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported financial results for the year ended December 31, 2020 and provided a summary of recent business and clinical highlights.
|
|
|
|
|
|
|
|
Zymeworks Expands Commercial Team and Creates New R&D Role
|
|
Vancouver, BC, February 10, 2021--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that James Priour, former Senior Vice President, Commercial, has been promoted to Chief Commercial Officer and named to the Company's Executive Committee.
|
|
|
|
|
|
|
|
|
|
|
|
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia, Zymeworks to receive US$10 million milestone payment from BeiGene
|
|
Vancouver, BC, December 6, 2020--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that its partner, BeiGene, Ltd., has dosed the first patient in South Korea in a pivotal, single-arm clinical trial of zanidatamab (formerly ZW25) monotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer (BTC).
|
|
|
|
|
|
|
|
|
|
|
|
Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148
|
|
Vancouver, BC, November 24, 2020--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NASDAQ: ALXO), announced they have entered into a clinical collaboration to evaluate the combination of Zymeworks' zanidatamab (formerly ZW25), a HER2-targeted bispecific antibody, and ALX148, a next-generation CD47 blocker, for the treatment of patients with advanced HER2-expressing breast cancer and other solid tu
|
|
|
|
|
|
|
|
Zymeworks Reports 2020 Third Quarter Financial Results
|
|
Vancouver, BC, November 9, 2020--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, has reported financial results for the quarter ended September 30, 2020.
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
